Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 14 Jan 2026
In a phase 3 trial, the first-in-class triple agonist delivered up to an average of 71.2 lbs weight loss and reduced WOMAC pain scores for knee osteoarthritis.
Read Full NewsThe rheumatology month in review emphasizes new data presented at the 2025 ACR Convergence.
A compilation of 13 trials presented as late-breaking data at ACR Convergence 2025.
New research at ACR 2025 highlights the link between cognitive impairment and disease activity in SLE.
Explore groundbreaking advancements in healthcare as 2025 concludes, featuring expert insights and dynamic multimedia.
This rheumatology month in review emphasizes new data from the ACR Convergence.
New data support firsekibart's efficacy over colchicine for preventing acute gout flares.
A new study reveals ligdolinurad effectively lowers uric acid levels in gout patients, showcasing promising safety and tolerability results.
1.
Unified Neuro/Psych Residency Program: New Proposal.
2.
Ignoring Colonoscopy Advice; Dry Mouth Acupuncture; Inflamed Tongue, Then Cancer.
3.
Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival
4.
AI is equally capable of reading breast cancer scans as human radiologists.
5.
Unlocking the potential of targeted therapies for multiple myeloma
1.
Revolutionizing Cancer Treatment: Harnessing the Power of AI in Histopathology
2.
Unlocking the Benefits of Cyramza: A New Frontier in Cancer Treatment
3.
Exploring Digital Cognitive Stimulation for Elderly Breast Cancer Patients
4.
AI Meets the Gut Microbiome: Early Detection of GI Malignancies Redefined
5.
HSC Failure in Fanconi Anemia: Mechanisms, Models, and Emerging Therapeutic Pathways
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
3.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
4.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
5.
Navigating the Complexities of Ph Negative ALL - Part XVI
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge